Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go:
TBC
investment:
£127,001
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go:
Extended
investment:
£295,000
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go:
Extended
investment:
Withheld
Plerith works with high growth start-ups and scaling companies to plan for and deliver growth. The company asserts that it helps companies promote their business to potential funders, through its network of angel and venture capital investors depending on the stage and sector of the said business. Plerith is partnering with Newable and Bristol Private Equity Club to deliver the fund in the South West London (SWL) area and identify and invest in the most exciting high growth companies in the region. Plerith argues that its deep knowledge of fundraising, sales, strategy, finance and technology would help SWL businesses flourish. Plerith aims to provide investors access to the highest quality local companies in the SWL region.
days to go:
Stretch
investment:
Withheld
Elfin Market aims to revolutionize the credit card industry by making credit cards more affordable, fair, and straightforward. They launched the Elfin Card, offering flexible credit that is 50% cheaper than the average credit card, featuring transparent pricing and state-of-the-art iOS and Android apps for real-time account management. The company operates on a flat servicing fee of 2.5% before transferring interest from borrowers to lenders, providing a simpler and more cost-effective credit solution.
days to go:
Expired
investment:
£1,390,059
Saurus is a digital banking platform that aims to make all banking services accessible to its users from the convenience of their smartphones. The company aims to develop a current account facility and contactless payments between their users' smartphones, and eventually venture into saving accounts, Automatic A.I Loans, P2P Loans, Investment account, Instant transfers, and Personalized Debit Cards. The company has a growing online presence with 133,000+ YouTube and 700+ Instagram followers with 1500 users registering on the portal with negligible marketing activities. In February 2020, more than a 1000 people showed interest in opening a Saurus account. With the investment, the company aims to launch the Saurus App with 'Current Accounts' features during Q3 2020, hire qualified professionals to expand the brand, and sign appropriate contracts with its providers.
days to go:
Expired
investment:
£943,540
Receive an affordable massage at home and on-demand by easily booking straight from an app. Since the start of year, Urban Massage has delivered more than 114,000 massages and received a 4.85/5 or above rating for the level of treatment provided to their customers. The company has successfully launched in Birmingham, Manchester and Paris with an Annualised Run Rate (ARR) of 3,300% from June 2014 and in June 2018, an ARR of £10.4m.
days to go:
Expired
investment:
£3,491,730
PathCloud aims to assemble the global clinical diagnostics resources and data and make them safely available and helpful. The company has created and tested one of the first scalable clinical diagnostics management platforms. It currently has 20,000 clinicians partner networks and 92 registered clinicians. Additionally, it has a network across 48 counties, has over 100 providers, over 3500 diagnostics tests registered and over 10,000 patients by partner telemedicine networks. These funds will be used to gain a significant portion of diagnostics supplier agreements towards the scaling objective, increase efforts towards the international markets and NHS and pursue telemedicine networks.
days to go:
Expired
investment:
£81,720
British Pearl is a property investment platform facilitating share & loan investment in property. It is an FCA authorised investment manager which allows fractional international investment in the property without any hassle. British Pearl has won ten award nominations, three speaker engagements and has been featured in over 20 media including the Times, the Daily Mail and the BBC. With the proceeds, the company will grow the sales, increase property sourcing and develop the platform's features.
days to go:
Expired
investment:
£910,132
Rescape is a company pioneering the use of Virtual Reality (VR) in healthcare and frontline services. Its DR.VR platform, launched in 2019, helped reduce pain and anxiety amongst patients in hospitals and care homes. The company delivers VR content to patients through the Samsung Gear VR headset, a hard-plastic headset, that can be wiped down and disinfected along with VR sanitary eye masks that reduce chances of infection and irritation to patients. Through the company's technology, patients can experience ocean life, amusements parks and relax in some of the most beautiful settings in the world, all from the safety of the healthcare institution. The AR/VR in Healthcare Market is predicted to reach USD 30-40 billion by 2026, and Rescape aims to be a disruptor in this segment. The company will use the investment to grow its business across different verticals.
days to go:
Expired
investment:
£488,450
